OCA
GLUE icon

OpenArc Corporate Advisory’s Monte Rosa Therapeutics GLUE Stock Holding History

OpenArc Corporate Advisory’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100,227
Closed -$1.65M – 808
2026
Q1 		$1.65M Buy
+100,227
New +$1.92M 0.02% 268

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OpenArc Corporate Advisory's GLUE Position: Q2 2026 in Review

OpenArc Corporate Advisory sold out of Monte Rosa Therapeutics (GLUE) in Q2 2026, closing a stake of 100,227 shares — an estimated $1.65M sold.

OpenArc Corporate Advisory first reported a position in GLUE in Q1 2026 and held it in 1 quarter. The position peaked at $1.65M in Q1 2026. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • OpenArc Corporate Advisory reported no remaining Monte Rosa Therapeutics position as of Q2 2026 after selling out during the quarter.
  • OpenArc Corporate Advisory sold 100,227 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.65M.
  • OpenArc Corporate Advisory first reported a position in Monte Rosa Therapeutics in Q1 2026 and held it in 1 quarter.
  • OpenArc Corporate Advisory's Monte Rosa Therapeutics position peaked at $1.65M in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.